BCIQ Profiles

Company Profile Report

AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity

The rationale behind the only AAV-based vaccine in development for COVID-19

The academic team behind the only AAV vaccine candidate for COVID-19 thinks its vector can get the best of both worlds and induce stronger antibody responses than adenoviral vaccines, while still activating T cells. Moreover, the researchers contend it can avoid viral vectors' Achilles heel: pre-existing immunity.

The dominant focus for COVID-19 vaccine development has been on their ability to generate antibodies against SARS-CoV-2, the virus that causes the disease. Whereas generating antibodies is the domain of B cells, their counterpart role of T cells has received less attention.

Activating T cell immunity brings multiple advantages, including recruiting CD4+ T cells that help B cells develop more potent antibody responses, and CD8+ T cells that kill infected cells directly.

Vectors encoding viral antigens are thought to be among the most efficient at

Read the full 1304 word article

How to gain access

Continue reading with a
two-week free trial.